Bladder Cancer Diagnostics Market Size to Reach USD 3,916.5 million in 2032

(MENAFN- Navistrat Analytics) September 05, 2025- The expanding application of near-infrared spectroscopy (NIRS) in pharmaceuticals and healthcare is a key factor driving revenue growth in the market. NIRS is a noninvasive technique used to measure tissue oxygen saturation in organs such as the brain, kidneys, and gut. By analyzing changes in the attenuation of near-infrared light passing through the brain, it provides measurements of cerebral regional oxygen saturation (CrSO₂). In neonatal intensive care units (NICUs), NIRS has become increasingly valuable for monitoring extremely preterm infants and neonates with conditions such as encephalopathy, congenital heart disease (CHD), anemia, respiratory distress, and brain injury.

In September 2024, SpectraWAVE, Inc.—a medical imaging company dedicated to enhancing treatment and outcomes for patients with coronary artery disease (CAD)—secured a USD 50 million Series B funding round. The investment was led by Johnson & Johnson Innovation – JJDC, Inc., with participation from S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture, and Heartwork Capital, underscoring investor confidence in NIRS-related innovations.

Beyond healthcare, rapid, and accurate analysis is becoming increasingly critical for quality assurance, authenticity testing, and food safety in the evolving food industry landscape. Near-infrared spectroscopy has gained strong traction as a non-destructive, fast, and environmentally friendly analytical tool due to its versatility. However, its widespread integration into regulatory frameworks remains limited, with only 25 internationally recognized analytical method documents currently endorsing its application.

Segments market overview and growth Insights
Based on test type, the bladder cancer diagnostics market is segmented into urine culture test, urine biomarker tests, imaging tests, invasive diagnostic procedures, and others. The invasive diagnostic procedures segment accounted for the largest market share in 2024. Cystoscopy remains the standard approach for diagnosing bladder cancer, as it is considered low-risk and enables both biopsy sampling and the removal of papillary tumors in a single procedure. Typically performed as an outpatient intervention under general anesthesia, cystoscopy with bladder biopsies provides effective diagnostic and therapeutic benefits. Flexible cystoscopy offers accuracy comparable to rigid cystoscopy but is significantly better tolerated, particularly among male patients.

Regional market overview and growth insights
Europe held the largest market share in the Bladder Cancer Diagnostics market in 2024. The market is being driven by rising incidence of bladder cancer and technological advancements in diagnostic methods. In the United States, bladder cancer ranks as the fourth most common cancer among men, the eighth among women, and the fifth overall, with men being affected about four times more often than women. According to the National Cancer Institute, there were 82,290 newly diagnosed cases and 16,710 deaths from bladder cancer in 2023. The disease represents 4.2% of all new cancer cases and 2.7% of all cancer-related deaths in the country, with a reported 5-year relative survival rate of 77.9%.

Competitive Landscape and Key Competitors
The Bladder Cancer Diagnostics market is characterized by a fragmented structure, with many competitors holding a significant share of the market. list of major players included in the Bladder Cancer Diagnostics market report are:

o Abbott
o Cepheid
o A. Menarini Diagnostics s.r.l
o Veracyte, Inc.
o Exact Sciences
o Pacific Edge
o QIAGEN
o Nanoentek
o Nonagen Bioscience Corporation
o Sysmex Corporation
o VitaDX
o Pangea Laboratory
o AIRA Matrix
o KARL STORZ
o Natera, Inc.

Major strategic developments by leading competitors
Roche: In September 2024, Roche broadened its digital pathology open platform by integrating over 20 advanced artificial intelligence (AI) algorithms developed through collaborations with eight new partners. These partnerships are designed to support pathologists and researchers in cancer detection and research by leveraging state-of-the-art AI innovations.

Scinvivo: In February 2024, Scinvivo, a medtech company based in Eindhoven focused on advancing bladder cancer diagnostics, secured Euro 4.7 million in funding from Santec OIS Corporation and The NLC Health Impact Fund. The investment will support the development of its catheter, OCT system, and accompanying software, with the goal of enabling clinical use and increasing adoption among urologists.


Navistrat Analytics has segmented the Bladder Cancer Diagnostics market based on test type, technology, cancer type, end-use, and region:

• Test Type Outlook (Revenue, USD Million; 2022-2032)
o Urine Culture Test
o Urine Biomarker Tests
o Imaging Tests
o Invasive Diagnostic Procedures
o Others

• Technology Outlook (Revenue, USD Million; 2022-2032)
o Immunoassay
o Flow Cytometry
o Fluorescence In Situ Hybridization (FISH)
o PCR and NGS
o Chromatography & Mass Spectrometry

• Cancer Type Outlook (Revenue, USD Million; 2022-2032)
o Transitional cell bladder cancer
o Invasive bladder cancer
o Superficial bladder cancer
o Squamous cell bladder cancer
o Others

• End-Use Outlook (Revenue, USD Million; 2022-2032)
o Hospitals
o Diagnostic Centers
o Academic Institutions
o Ambulatory Surgical Center

• Regional Outlook (Revenue, USD Million; 2022-2032)
o North America
a. U.S.
b. Canada
c. Mexico
o Europe
a. Germany
b. France
c. U.K.
d. Italy
e. Spain
f. Benelux
g. Nordic Countries
h. Rest of Europe
o Asia Pacific
a. China
b. India
c. Japan
d. South Korea
e. Oceania
f. ASEAN Countries
g. Rest of APAC
o Latin America
a. Brazil
b. Rest of LATAM
o Middle East & Africa
a. GCC Countries
b. South Africa
c. Israel
d. Turkey
e. Rest of MEA

@Navistrat Analytics

MENAFN05092025008152017457ID1110022434